On Friday, Nuvation Bio Inc (NYSE: NUVB) opened lower -3.91% from the last session, before settling in for the closing price of $2.30. Price fluctuations for NUVB have ranged from $0.95 to $4.16 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted -501.14% at the time writing. With a float of $227.21 million, this company’s outstanding shares have now reached $334.78 million.
In an organization with 51 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -3.53%, operating margin of -6632.37%, and the pretax margin is -30060.04%.
Nuvation Bio Inc (NUVB) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Nuvation Bio Inc is 32.13%, while institutional ownership is 39.13%. The most recent insider transaction that took place on Oct 08 ’24, was worth 220,000. In this transaction Director of this company bought 100,000 shares at a rate of $2.20, taking the stock ownership to the 100,000 shares. Before that another transaction happened on Jun 25 ’24, when Company’s Director bought 277,895 for $2.97, making the entire transaction worth $825,348. This insider now owns 2,453,131 shares in total.
Nuvation Bio Inc (NUVB) Performance Highlights and Predictions
If we go through the results of last quarter, which was made public on 6/30/2024, the company posted -0.09 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.11) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -501.14% per share during the next fiscal year.
Nuvation Bio Inc (NYSE: NUVB) Trading Performance Indicators
Check out the current performance indicators for Nuvation Bio Inc (NUVB). In the past quarter, the stock posted a quick ratio of 11.49. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 513.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.11, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.58 in one year’s time.
Technical Analysis of Nuvation Bio Inc (NUVB)
Let’s dig in a bit further. During the last 5-days, its volume was 1.15 million. That was inferior than the volume of 1.42 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.83%. Additionally, its Average True Range was 0.18.
During the past 100 days, Nuvation Bio Inc’s (NUVB) raw stochastic average was set at 10.66%, which indicates a significant decrease from 35.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.49% in the past 14 days, which was higher than the 70.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.66, while its 200-day Moving Average is $2.69. However, in the short run, Nuvation Bio Inc’s stock first resistance to watch stands at $2.28. Second resistance stands at $2.36. The third major resistance level sits at $2.40. If the price goes on to break the first support level at $2.17, it is likely to go to the next support level at $2.13. Assuming the price breaks the second support level, the third support level stands at $2.05.
Nuvation Bio Inc (NYSE: NUVB) Key Stats
There are currently 247,171K shares outstanding in the company with a market cap of 739.86 million. Presently, the company’s annual sales total 0 K according to its annual income of -75,800 K. Last quarter, the company’s sales amounted to 1,440 K and its income totaled -462,490 K.
